Ascletis’ NDA for Its All-oral HCV Treatment Accepted by CFDA
HANGZHOU, China and SHAOXING, China, Aug. 1, 2018 /PRNewswire/ — Ascletis announced today it has received the acceptance letter from the China Food and Drug Administration (CFDA) for Ravidasvir (RDV,…